Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer

• DOI: 10.1007/s00262-024-03782-7
• Publication Date: 2024-08-06T13:08:23Z
• Authors: Changhee Park; Koung Jin Suh; Se Hyun Kim; Kyung-Hun Lee; Seock-Ah Im; Min Hwan Kim; Joohyuk Sohn; Jae Ho Jeong; Kyung Hae Jung; Kyoung Eun Lee; Yeon Hee Park; Hee-Jun Kim; Eun Kyung Cho; In Sil Choi; Seung-Jae Noh; Inkyung Shin; Dae-Yeon Cho; Jee Hyun Kim
• Keywords: Eribulin

Biomarkers for predicting response to the immunotherapy and chemotherapy combination in breast cancer patients are not established. In this study, we report exploratory genomic transcriptomic analyses of pretreatment tumor tissues from enrolled phase II clinical trial a eribulin nivolumab HER-2-negative metastatic (MBC) (KORNELIA trial, NCT04061863).